According to the most recent CMS data, ∼67% of the insulin-treated Medicare beneficiaries who are currently treated with or will eventually transition to intensive insulin therapy are denied access to insulin pump therapy because of eligibility criteria that are medically unfounded.87 From our perspective, insulin pump therapy should be made available to all beneficiaries who would benefit from this technology, are motivated to achieve optimal glycemic control, and have the ability to safely and effectively use their insulin pump for daily diabetes self-management. The gene discussed is INS; the disease is diabetes mellitus.